BioCardia’s Cell Therapy Unlikely to Meet Primary Endpoint in Phase III Heart Failure

California-based BioCardia announced Tuesday that its clinical-stage experimental cell therapy for heart failure, CardiAMP, was unlikely to meet its primary endpoint based on preliminary data.